Neiromet (Capsules) Instructions for Use
ATC Code
N06BX13 (Idebenone)
Active Substance
Idebenone (Rec.INN registered by WHO)
Clinical-Pharmacological Group
Nootropic drug
Pharmacotherapeutic Group
Nootropic agent
Pharmacological Action
Nootropic agent with metabolic action. It enhances metabolic processes in the brain by activating the synthesis of glucose and ATP, improves blood supply and tissue oxygenation of the brain, promotes the elimination of lactates; increases the intensity and speed of neurophysiological reactions of brain structures.
By slowing down lipid peroxidation, it protects neuronal and mitochondrial membranes from damage.
From the first days of administration, an antiasthenic, psychostimulant and antidepressant effect is manifested; the nootropic effect appears after 3-4 weeks of administration.
Pharmacokinetics
Absorption is rapid and high; Tmax is 4 hours. It penetrates the blood-brain barrier in significant amounts and is distributed in brain tissues.
It does not accumulate. It is excreted by the kidneys.
Indications
Psycho-organic syndrome against the background of cerebrovascular disorders and age-related involutional changes of the brain; cerebroasthenic disorders of vascular, traumatic, psychogenic (neurasthenia) etiology: memory and/or attention disorders, decreased intellectual productivity and general activity, emotional lability; asthenic and astheno-depressive syndrome, moderately severe depressive syndrome; dizziness, tinnitus.
ICD codes
| ICD-10 code | Indication |
| F07 | Personality and behavioral disorders due to disease, damage or dysfunction of the brain |
| F31 | Bipolar affective disorder |
| F32 | Depressive episode |
| F33 | Recurrent depressive disorder |
| F41.2 | Mixed anxiety and depressive disorder |
| F48.0 | Neurasthenia |
| H93.1 | Tinnitus (subjective) |
| I67.2 | Cerebral atherosclerosis |
| I69 | Sequelae of cerebrovascular diseases |
| R42 | Dizziness and giddiness |
| T90 | Sequelae of injuries of head |
| ICD-11 code | Indication |
| 6A60.Z | Bipolar type I disorder, unspecified |
| 6A61.Z | Bipolar type II disorder, unspecified |
| 6A6Z | Bipolar or similar disorder, unspecified |
| 6A70.Z | Single episode depressive disorder, unspecified |
| 6A71.Z | Recurrent depressive disorder, unspecified |
| 6A73 | Mixed depressive and anxiety disorder |
| 6A8Z | Affective disorders, unspecified |
| 6C9Z | Disruptive behavior or dissocial disorders, unspecified |
| 6E68 | Secondary emotionally labile personality disorder |
| 6E6Z | Unspecified secondary mental or behavioral syndromes |
| 8B25.Z | Sequelae of cerebrovascular disease, unspecified |
| BD55 | Asymptomatic stenosis of intracranial or extracranial artery |
| MB48.Z | Dizziness and giddiness, unspecified |
| MC41 | Tinnitus |
| NA0Z | Head injury, unspecified |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Take the capsules orally with water.
Administer the drug after meals to improve tolerability.
The standard adult dosage is 30 mg taken two to three times daily.
Do not exceed the maximum daily dose of 90 mg.
Take the last dose of the day before 5 p.m. to prevent potential sleep disturbances.
The standard course of treatment is 1.5 to 2 months.
If clinically indicated, repeat the course; a maximum of two to three treatment courses per year are permitted.
Adhere strictly to the prescribed dosage and duration of therapy.
Do not adjust the regimen without consulting your physician.
Adverse Reactions
From the central nervous system: sleep onset disturbance, mental agitation, headache.
Other: dyspepsia, allergic reactions.
Contraindications
Chronic renal failure, hypersensitivity to the active substance.
Use in Pregnancy and Lactation
Use with caution during pregnancy and lactation.
Use in Renal Impairment
Contraindicated in chronic renal failure.
Special Precautions
Influence on the ability to drive vehicles and mechanisms
Do not take while working for vehicle drivers and patients whose profession requires high concentration of attention and speed of psychomotor reactions.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Rx Only
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical DisclaimerBrand (or Active Substance), Marketing Authorisation Holder, Dosage Form
Capsules 30 mg: 10 pcs.
Marketing Authorization Holder
Veropharm, JSC (Russia)
Dosage Form
| Neiromet | Capsules 30 mg: 10 pcs. |
Dosage Form, Packaging, and Composition
| Capsules | 1 caps. |
| Idebenone | 30 mg |
10 pcs. – blister packs (1) – cardboard packs.
Capsules 45 mg: 10 pcs.
Marketing Authorization Holder
Veropharm, JSC (Russia)
Dosage Form
| Neiromet | Capsules 45 mg: 10 pcs. |
Dosage Form, Packaging, and Composition
| Capsules | 1 caps. |
| Idebenone | 45 mg |
10 pcs. – blister packs (1) – cardboard packs.
